Skip to content

PolitiKit

Lobbying by Vimy Pharmaceuticals Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Vimy Pharmaceuticals Inc.

Meetings this Parliament
2
With MPs
1
Since Nov 2021
2
Active registrations
1

Most recent reported meeting: Sep 24, 2026.

Registrations in effect

Consultant In effect since Sep 24, 2026

Consultant Richard Maksymetz of Barrack Hill Public Affairs Inc.

Consultant lobbyists

  • Richard Maksymetz Former designated public office holder

    Formerly Chief of Staff, Office of the Minister, Finance Canada (2015–2018)

    Formerly Special Assistant, Office of the Leader of the Official Opposition, House of Commons (2007–2010)

    Formerly Special Assistant, Office of the Member of Parliament for Desnethé—Missinippi—Churchill River, House of Commons (2007–2007)

    Formerly Special Assistant, Office of the Minister, Transport Canada (2004–2006)

  • Richard Maksymetz Former designated public office holder

    Formerly Chief of Staff, Office of the Minister, Finance Canada (2015–2018)

    Formerly Special Assistant, Office of the Leader of the Official Opposition, House of Commons (2007–2010)

    Formerly Special Assistant, Office of the Member of Parliament for Desnethé—Missinippi—Churchill River, House of Commons (2007–2007)

    Formerly Special Assistant, Office of the Minister, Transport Canada (2004–2006)

Institutions they may lobby: Federal Economic Development Agency for Southern Ontario (FedDev), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Prairies Economic Development Canada (PrairiesCan), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Safety Canada (PS), Veterans Affairs Canada (VAC)

What they're lobbying on (1)
  • Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.

Registration 954762-384781-2. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by Richard Maksymetz · Consultant

    • Grace Pyne · Regional Advisor, Prairies Economic Development Canada (PrairiesCan)
    Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.

    Official report

  • Reported by Richard Maksymetz · Consultant

    Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.